Correction of the imbalance of ESR1-AKT-CREB-MYH signaling between two sides of para-spinal muscle by the FDA approved medicine Raloxifene mitigates the progression of AIS (Fig. 6g). The gene discussed is ESR1; the disease is androgen insensitivity syndrome.